HSA-approved treatments prescribed by licensed doctors, delivered with complete discretion.
We offer two
coordination options.
HSA-APPROVED CLINIC
Wegovy 7.2mg: Breaking Through Weight Loss Plateaus
Doctor-supervised weight management combining medical expertise with personalised care. Evidence-based. HSA-compliant. Results that last.
At NuLifeCare, we understand that every weight loss journey is unique. Some patients respond exceptionally well to standard-dose GLP-1 medications, while others reach a point where progress slows or stops entirely. If you have been consistent with your Wegovy 2.4mg treatment — taking your medication as prescribed, following dietary guidance, and maintaining physical activity — yet the scale has not moved in weeks or months, you are experiencing what clinicians call a weight loss plateau.
This is not a personal failure. It is a well-understood physiological response, and importantly, there is a new evidence-based option on the horizon: Wegovy 7.2mg — a higher-dose formulation of semaglutide now being imported into Singapore by NuLifeCare through the HSA Named Patient Programme.
Why Weight Loss Plateaus Happen — The Science Behind the Stall
A weight loss plateau occurs when the body adapts to a lower body weight and the energy deficit that initially drove weight loss narrows or disappears. Understanding the science behind plateaus is the first step to overcoming them.
Metabolic Adaptation: As you lose weight, your resting metabolic rate (RMR) declines — often by more than what your new weight would predict. A person who has lost 10% of their body weight may burn 300–400 fewer calories per day than someone of the same weight who was never heavier. This is called adaptive thermogenesis, and it is your body’s evolutionary mechanism for resisting further weight loss.
Hormonal Counter-Regulation: Weight loss increases ghrelin (the hunger hormone) and decreases leptin (the satiety hormone). Your brain receives stronger hunger signals and weaker fullness signals. GLP-1 receptor agonists like semaglutide work by targeting these pathways — but as weight loss progresses, the body’s counter-regulatory response intensifies. For some patients, even the 2.4mg maintenance dose cannot fully overcome these adaptive mechanisms.
The Case for Dose Escalation: For patients who tolerate semaglutide well at 2.4mg, increasing to 7.2mg is one clinically studied strategy to break through plateaus. The STEP UP trial was specifically designed to evaluate whether this higher dose could produce meaningful additional weight loss.
Dr. Joseph Wang
Licensed Family Physician · Registered with Singapore Medical Council
Every treatment plan begins with a comprehensive health assessment — including blood work, metabolic screening, and lifestyle evaluation — to determine the safest and most effective approach for your unique health profile. Your journey is guided by clinical evidence, monitored with regular follow-ups, and adjusted as your body responds. This is medical weight management — not a quick fix.
What Is Wegovy 7.2mg?
Wegovy 7.2mg is an investigational higher dose of semaglutide — three times the currently approved 2.4mg maintenance dose. It is being studied for patients who have demonstrated tolerance to the standard dose but whose weight loss has plateaued. Currently accessible in Singapore only through the HSA Named Patient Programme.
STEP UP Trial Results
A Phase 3 study (Jan 2023 – Nov 2024) found that fully adherent participants on Wegovy 7.2mg achieved up to 20.7% average weight loss. Crucially, patients plateaued on 2.4mg gained an additional 3% weight reduction after dose escalation.
HSA Named Patient Programme
NuLifeCare handles the entire HSA application process — medical documentation, submission, follow-up, and import logistics. You focus on your health journey; we manage the regulatory pathway. WhatsApp us at +65 9846 5594 to learn more.
The STEP UP Trial — Study Design, Results, and What It Means
The STEP UP trial was a Phase 3, randomised, double-blind clinical study conducted between January 1, 2023, and November 26, 2024. It enrolled adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity.
Key Results — Full Adherence: Among participants fully adherent to the treatment protocol and lifestyle modifications, Wegovy 7.2mg demonstrated an average weight loss of up to 20.7% of baseline body weight. This compares to approximately 17.5% typically observed with the 2.4mg dose.
Results for Plateau Patients: For patients whose weight loss had stalled on 2.4mg, transitioning to 7.2mg produced an additional average reduction of approximately 3%. While 3% sounds modest, it is clinically meaningful — for a 100kg patient, 3kg of additional weight reduction compounding on prior losses.
Secondary Benefits: The trial reported meaningful improvements in waist circumference, blood pressure, HbA1c, and lipid profiles — particularly relevant for patients whose obesity is complicated by related health conditions.
What Is Medical Weight Loss and How Does It Work?
Medical weight loss uses HSA-approved prescription treatments combined with doctor supervision to target the biological drivers of weight gain. Unlike commercial slimming programmes, medical weight management addresses the hormones that regulate appetite, satiety, and metabolism.
The cornerstone treatment class is GLP-1 receptor agonists. These medications mimic the naturally occurring GLP-1 hormone:
Appetite suppression: Signals the brain that you are full, reducing hunger.
Slowed gastric emptying: Food stays in the stomach longer, prolonging satiety.
Improved insulin sensitivity: Better blood sugar control reduces cravings.
Calorie reduction: Clinical studies show patients naturally consume 25-35% fewer calories.
According to the New England Journal of Medicine (2021), patients on GLP-1 treatment combined with lifestyle modification achieved substantially greater weight reduction than lifestyle modification alone.
Accessing Wegovy 7.2mg Through the HSA Named Patient Programme
The Named Patient Programme (NPP) is a regulated HSA pathway allowing registered medical practitioners to import unregistered therapeutic products for individual patients when there is a genuine clinical need that cannot be met by registered alternatives.
How the NPP works at NuLifeCare:
- Initial Consultation: Doctor assesses your weight loss history, plateau status, and tolerability
- HSA Application: NuLifeCare prepares and submits the full NPP application on your behalf — including medical rationale, doctor credentials, and product documentation
- HSA Review: HSA processes the application, typically within 2–4 weeks
- Product Shipment: Upon approval, medication is ordered from the manufacturer and shipped under controlled conditions
- Clinic Delivery: You are notified when the medication arrives for collection and administration
Patients do not interact with HSA or handle any regulatory paperwork. NuLifeCare manages the entire process.
Import Timeline — What to Expect
The overall process may take up to eight weeks from initial consultation to receiving treatment:
Stage 1 — Medical Consultation: Same-day assessment of suitability and medical history review.
Stage 2 — HSA Application: 2–4 weeks. The clinic submits documentation; HSA reviews and approves.
Stage 3 — Product Shipment: 2–3 weeks. Medication ordered from manufacturer and shipped to Singapore.
Stage 4 — Clinic Delivery: ~1 week. Medication arrives at NuLifeCare; you are contacted to schedule collection.
Actual durations depend on HSA processing volumes, manufacturer stock availability, and shipping logistics. We keep you updated at every stage.
Safety and Side Effect Profile
The STEP UP trial safety data are consistent with the established profile of semaglutide:
- Nausea: ~40–45% of participants, mostly mild to moderate
- Diarrhoea: 20–25%
- Vomiting: 15–20%
- Constipation: 15–20%
Side effects occurred most frequently during dose escalation and tended to diminish over time. Discontinuation rates due to GI effects were comparable to the 2.4mg dose. No new safety signals emerged at 7.2mg. Your doctor reviews your complete medical history before recommending dose adjustment.
Why Choose NuLifeCare for Wegovy 7.2mg
- Doctor-Led Care: Every patient assessed and managed by Dr Joseph Wang, an experienced family physician
- NPP Expertise: One of few Singapore clinics with direct experience importing through the Named Patient Programme
- Comprehensive Follow-Up: Regular consultations for dose adjustments, side effect management, and lifestyle guidance
- Integrated Programme: Medication combined with dietary guidance, physical activity counselling, and behavioural support
- Transparent Communication: You know what to expect at every stage — from consultation through HSA approval to treatment delivery
Frequently Asked Questions
Can I switch directly from Wegovy 2.4mg to 7.2mg?
Dose escalation protocols are determined by the prescribing doctor based on your individual medical assessment. The transition is medically supervised. Your doctor may recommend an intermediate dose step or a gradual titration schedule depending on your tolerance and clinical needs.
What if I am not currently on Wegovy 2.4mg?
Wegovy 7.2mg through the Named Patient Programme is being considered for patients already on the 2.4mg maintenance dose. If you are new to medical weight management, your doctor will recommend the most appropriate starting point — typically 0.25mg once weekly, increasing gradually over 16–20 weeks to reach the 2.4mg maintenance dose.
Does NuLifeCare handle the HSA paperwork?
Yes. NuLifeCare manages the entire HSA Named Patient Programme application process — from preparing the medical documentation to submitting the application and following up with HSA. You do not need to file any documents with HSA yourself. We keep you informed of the application status throughout the process.
Is the 7.2mg dose safe?
The STEP UP trial data indicate a safety profile consistent with the known effects of GLP-1 receptor agonists at therapeutic doses. The most common side effects — nausea, diarrhoea, vomiting, and constipation — were generally mild to moderate and improved over time. As with any prescription medication, the decision to escalate must be individualised by your treating doctor after reviewing your complete medical history.
How do I start the process?
The first step is a medical consultation at NuLifeCare. Contact us at 6844 1528, WhatsApp us at +65 9846 5594, or book through our online booking page. During the consultation, our doctor will review your weight loss history, assess your plateau status, and determine whether Wegovy 7.2mg is appropriate for you.
How much does Wegovy 7.2mg cost?
As Wegovy 7.2mg is imported through the Named Patient Programme rather than standard commercial channels, the cost depends on factors including manufacturer pricing, shipping and handling, and the HSA application process. During your consultation, we provide a transparent breakdown of all associated costs so you can make an informed decision.
Can I combine Wegovy 7.2mg with other weight loss treatments?
Your doctor will review all medications and treatments you are currently using. The decision to combine treatments is made on an individual basis after a thorough medical assessment. Never combine prescription medications without explicit medical supervision.
What happens after I reach my goal weight on Wegovy 7.2mg?
Long-term weight management involves an individualised maintenance plan developed with your doctor. This may include ongoing medication at an appropriate dose, continued lifestyle modifications, and regular follow-up to prevent weight regain. Your doctor will guide you through each phase of the journey.
Medical Disclaimer: This page is for informational purposes only and does not constitute medical advice. Wegovy (semaglutide) is a prescription-only medicine that must be prescribed by a registered medical practitioner following an individual medical assessment. Always consult a qualified healthcare professional for medical concerns, diagnosis, or treatment. Individual results vary. The STEP UP trial data referenced on this page is from published clinical research. NuLifeCare is registered with ACRA under UEN 202526802Z.
Ready to Break Through Your Weight Loss Plateau?
NuLifeCare is one of the few clinics in Singapore directly importing Wegovy 7.2mg under the HSA Named Patient Programme. If you are currently on Wegovy 2.4mg and your weight has plateaued, speak with our medical team about whether the higher dose is right for you.
📞 6844 1528 | 📱 WhatsApp: +65 9846 5594 | 📧 contact@nulifecare.com.sg
📍 Blk 325 Ubi Avenue 1 #01-701, Singapore 400325